This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-27 and is reviewed periodically as new material appears.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
In 2005, 51 million Brazilian nationals made ten times more trips than foreign tourists and spent five times more money than their international counterparts. The main destination states in 2023 were São Paulo, Rio de Janeiro, and Rio Grande do Sul. The main source of tourists for the entire country is São Paulo state. In terms of tourism revenues, the top earners by state were São Paulo and Bahia. For 2005, the three main trip purposes were visiting friends and family (53.1%), sun and beach (40.8%), and cultural tourism (12.5%).
=== Paleontology === Although the word dinosaur can be used pejoratively to describe something that is becoming obsolete due to failing to adapt to changing conditions, non-avian dinosaurs did not become extinct due to being generally maladapted or unable to cope with normal climatic change, a view found in many older textbooks. Moreover, not all dinosaurs are extinct (see below). Dinosaurs are not extinct, as birds are classified within the theropod dinosaur lineage. The word dinosaur is commonly used to refer only to non-avian dinosaurs, reflecting an outdated conception of the ancestry of avian dinosaurs, the birds. The evolutionary origin of birds was an open question in paleontology for over a century, but the modern scientific consensus is that birds evolved from small feathered theropods in the Jurassic. Not all dinosaur lineages were cut short at the end of the Cretaceous during the Cretaceous–Paleogene extinction event, and over 11,000 species of avian theropods survive as part of the modern fauna. Dinosaurs, pterosaurs, and ichthyosaurs were not cold-blooded. Dinosaur thermoregulation is a topic of ongoing study. However, their high growth rates and the presence of dinosaur fossils in cold polar climates make cold-bloodedness implausible. Pterosaurs are inferred to be warm-blooded because they had a hair-like body covering, a trait absent in modern cold-blooded animals. Estimates of ichthyosaur body temperature are similar to marine mammals in every climate.
A stew is a combination of solid food ingredients that have been cooked in liquid and served in the resultant gravy. Ingredients can include any combination of vegetables and may include meat, especially tougher meats suitable for slow-cooking, such as beef, pork, venison, rabbit, lamb, poultry, sausages, and seafood. While water can be used as the stew-cooking liquid, stock is also common. A small amount of red wine or other alcohol is sometimes added for flavour. Seasonings and flavourings may also be added. Stews are typically cooked at a relatively low temperature (simmered, not boiled), allowing flavours to mingle.
Sources: en.wikipedia.org
=== Debridement === Debridement is defined as removal of devitalized or dead tissue, particularly necrotic tissue, eschar, or slough. Debridement is a critical aspect of wound care because devitalized tissue, particularly necrotic tissue, serves as nutrients for bacteria thereby promoting infection. Additionally, devitalized tissue creates a physical barrier over a wound which limits the effectiveness of any applied topical compounds and prevents re-epithelialization. Lastly, devitalized tissue, especially eschar, prevents accurate assessment of underlying tissue, making appropriate assessment of a wound impossible without adequate debridement. Debridement can be achieved in several ways:
Treatment of depression: Used in adults who may present with symptoms of anxiety, low mood, lack of enthusiasm, and restlessness. Treatment of anxiety: Indicated for patients with anxiety disorders, especially when depression is also present or when there is associated asthenia (unexplained fatigue or weakness). Management of asthenia: Used for conditions characterized by fatigue, low energy, and diminished motivation, frequently seen with mood disturbances. Psychosomatic and neurotic disorders: Recommended for depressive neuroses, psychogenic depression, masked depression, neurasthenia, and psychosomatic affections where anxiety, depression, or apathy are prominent. Menopausal depression: Often indicated for mood changes associated with menopause. Depression in alcoholics and drug addicts: Used in cases where mood disorders accompany substance dependence.
Louise Rummel, nurse and nursing educator (Manukau Institute of Technology) (born 1937). 22 August Denis Cameron, rugby union player (Mid Canterbury, Counties, national team) (born 1938). Michael Henderson, fencer, British Empire and Commonwealth Games bronze medallist (1962) (born 1935). 23 August – John Roy-Wojciechowski, Polish community leader and philanthropist (born 1933). 24 August – John Barnett, film and television producer (Footrot Flats: The Dog's Tale, Whale Rider, Sione's Wedding) (born 1945). 27 August Shane Christie, rugby union player (Tasman, Highlanders, Māori All Blacks) (born 1985). Dame Peggy Koopman-Boyden, gerontologist (University of Waikato) (born 1943). 29 August – Jay Shaw, philosopher (Victoria University of Wellington) (born 1941).
Kleptomania A psychiatric disorder characterized by recurrent urges to steal items not needed for personal use or value. Considered in neuropsychiatry as a type of impulse control disorder involving frontal lobe dysfunction. Klüver–Bucy syndrome A behavioral disorder caused by bilateral lesions of the amygdala and temporal lobes, resulting in hyperorality, hypersexuality, and emotional blunting. Knock-in A genetic technique where a gene is replaced or inserted at a specific locus, allowing researchers to study the function of specific mutations in neural systems. Knockout mouse A genetically engineered mouse in which one or more genes have been turned off through targeted mutation. Frequently used to study gene function in brain development and behavior. Korsakoff syndrome A chronic memory disorder caused by thiamine (vitamin B1) deficiency, most commonly due to chronic alcohol misuse. It involves degeneration of the mammillary bodies and medial thalamus. Krebs cycle (Citric acid cycle) A key metabolic pathway that provides energy to neurons. Although a general biology term, it is critical in neuroscience for understanding brain metabolism and mitochondrial function. Kymograph An old device used to record changes in physiological activity over time, such as muscle contractions or nerve responses. Historically significant in neuroscience research.
Sources: en.wikipedia.org
== Origins of microscopic pathology == Rudolf Virchow (1821–1902) is generally recognized to be the father of microscopic pathology. While the compound microscope had been invented approximately 150 years prior, Virchow was one of the first prominent physicians to emphasize the study of manifestations of disease which were visible only at the cellular level. A student of Virchow's, Julius Cohnheim (1839–1884) combined histology techniques with experimental manipulations to study inflammation, making him one of the earliest experimental pathologists. Cohnheim also pioneered the use of the frozen section procedure; a version of this technique is widely employed by modern pathologists to render diagnoses and provide other clinical information intraoperatively.
Of Molecules and Men (Prometheus Books, 2004; original edition 1967) ISBN 1-59102-185-5 Life Itself: Its Origin and Nature (Simon & Schuster, 1981) ISBN 0-671-25562-2 What Mad Pursuit: A Personal View of Scientific Discovery (Basic Books reprint edition, 1990) ISBN 0-465-09138-5 The Astonishing Hypothesis: The Scientific Search for the Soul (Scribner reprint edition, 1995) ISBN 0-684-80158-2 Georg Kreisel: a Few Personal Recollections. In: Kreiseliana: About and Around Georg Kreisel (1996), pp. 25–32. ISBN 1-56881-061-X
== History == Vosilasarm was developed by Radius Health in 2010. It was first described in the literature in 2011 in a paper detailing its design, synthesis, and preclinical characterization in vitro and in rats and monkeys. It was stated in this paper that phase 1 clinical studies of vosilasarm for treatment of severe weight loss due to cancer cachexia were being prepared. However, these studies were never completed or published and development for this indication was discontinued. Subsequently, vosilasarm was repurposed for the treatment of breast cancer.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.